Ringing the opening bell today, a mental health unicorn is born — ATAI is now the most valuable psychedelic company, with a broad array of therapies in development for depression, PTSD, anxiety, substance abuse, TBI and cognitive impairment.
Depression is the leading cause of disability worldwide, and the World Health Organization predicts that – without significant changes – mental illness will cost the world economy $16 trillion by 2030, making it the largest disease burden globally.
And then, COVID-19 happened, and the prevalence of depression tripled.
With psychedelic therapy showing the most promise of any mental treatment ever for depression and PTSD (67% cure rates), significant change is coming. Over time, atai is addressing the whole DSM-5.
ATAI Intro video. And it was Future Ventures’ second IPO of 2021 too!
Leave a Reply